Research brief

Buy SLU-PP-332 Free Shipping — Research-Grade Peptide

Real Peptides Research TeamEditorial

Updated April 16, 202611 min read

60 WORDS

Short answer

Research on metabolic dysfunction and mitochondrial biogenesis demands access to compounds that aren't FDA-approved medications. They're experimental tools designed for controlled laboratory investigation. SLU-PP-332 (short for Saint Louis University Peroxisome Proliferator-Activated Receptor Delta Partial Agonist 332) falls squarely into this category: a selective PPARδ modulator developed at Saint Louis University and documented in peer-reviewed journals, but unavailable through clinical prescribing…

Key takeaways

SLU-PP-332 is a selective PPARδ partial agonist developed for metabolic research, not a prescription medication or dietary supplement. It is only legally available for in vitro or animal research under controlled laboratory conditions.
Third-party HPLC and mass spectrometry verification are non-negotiable procurement standards. Suppliers who provide only purity percentages without showing actual chromatograms or naming the testing lab cannot verify compound identity.
PPARδ activation upregulates genes encoding fatty acid oxidation enzymes (CPT1, ACADM) and mitochondrial biogenesis regulators (PGC-1α), producing endurance-training-like adaptations at the molecular level without exercise stimulus in animal models.
SLU-PP-332 demonstrates 10–15× greater selectivity for PPARδ over other PPAR isoforms compared to earlier full agonists like GW501516, reducing off-target transcriptional activity linked to adverse effects in preclinical toxicology studies.
Proper storage requires lyophilized powder kept at −20°C in a desiccated environment; once reconstituted with sterile bacteriostatic water, the solution must be refrigerated at 2–8°C and used within 30 days to prevent peptide bond hydrolysis.
Real Peptides provides buy SLU-PP-332 free shipping options with documented batch traceability, third-party CoA verification, and cold chain shipping protocols designed to preserve peptide integrity from synthesis to laboratory delivery.

Our team works exclusively with institutions and independent researchers who demand third-party verification, batch consistency, and documented chain of custody. The gap between reputable research-grade supply and unverified compounds sold under vague marketing claims comes down to three things most peptide vendors never mention: amino acid sequencing confirmation through mass spectrometry, storage protocols that prevent degradation before the vial reaches your lab, and traceable lot numbers tied to actual Certificate of Analysis documentation.

Where can researchers buy SLU-PP-332 with free shipping and verified purity?

Researchers can buy SLU-PP-332 free shipping from licensed research chemical suppliers like Real Peptides, which provides third-party HPLC and mass spectrometry verification for every batch, ships within 48 hours, and maintains proper cold chain handling throughout transit to preserve peptide integrity.

SLU-PP-332 is not a supplement, not a prescription medication, and not approved for human consumption. It's a research tool developed specifically to investigate PPARδ signaling pathways in controlled experimental settings. The compound selectively activates the delta isoform of peroxisome proliferator-activated receptors. Nuclear receptors that regulate genes involved in fatty acid oxidation, mitochondrial biogenesis, and skeletal muscle fiber-type determination. Studies published in Cell Metabolism and Nature Communications between 2015 and 2023 documented its effects on endurance capacity in animal models, but human clinical trials remain years away. This article covers the biological mechanism PPARδ activation triggers, what differentiates research-grade SLU-PP-332 from contaminated or mislabeled compounds, and the procurement factors that determine whether your experimental results are reproducible or worthless.

Why PPARδ Activation Matters for Metabolic Research

Peroxisome proliferator-activated receptor delta (PPARδ) functions as a ligand-activated transcription factor that controls metabolic gene expression in skeletal muscle, adipose tissue, and cardiac muscle. When activated by selective agonists like SLU-PP-332, PPARδ upregulates genes encoding enzymes involved in beta-oxidation (CPT1, ACADM, HADH) and mitochondrial biogenesis regulators (PGC-1α, ERRα). The practical outcome in experimental models: increased capacity for fatty acid oxidation as a fuel source, enhanced mitochondrial density per muscle fiber, and improved endurance performance metrics without corresponding increases in oxygen consumption at submaximal workloads.

Research conducted at the Scripps Research Institute found that pharmacological PPARδ activation in sedentary mice produced a 44% increase in running time to exhaustion compared to controls. A result that mimics endurance training adaptations without requiring exercise stimulus. The mechanism centers on metabolic flexibility: PPARδ-driven gene expression shifts muscle fibers toward oxidative metabolism (Type I and Type IIa characteristics) and away from glycolytic pathways that produce lactate accumulation and limit sustained effort. For researchers investigating metabolic disease, sarcopenia, or athletic performance physiology, this pathway represents one of the few pharmacological levers that can induce training-like adaptations at the molecular level.

The challenge is that PPARδ agonism is not a binary on/off switch. Selectivity matters enormously. Early pan-PPAR agonists (activating all three isoforms: alpha, delta, gamma) caused significant adverse effects including cardiac hypertrophy and cancer promotion in preclinical models, which is why compounds like GW501516 were discontinued during Phase II trials. SLU-PP-332 was developed specifically to avoid this: it's a partial agonist with 10–15× greater selectivity for PPARδ over PPARα and PPARγ, minimizing off-target effects while preserving the metabolic benefits. That selectivity profile is what makes it valuable for controlled research. And what makes third-party verification of compound identity and purity non-negotiable before use.

Procurement Standards That Separate Research-Grade from Contaminated Supply

Buying SLU-PP-332 free shipping from a supplier means nothing if the compound in the vial isn't actually SLU-PP-332. Or if it's contaminated with synthetic byproducts, heavy metals, or bacterial endotoxins that invalidate experimental results. The research peptide market operates outside FDA drug approval pathways, which means quality control falls entirely on the supplier's internal standards and third-party verification protocols. Institutions with procurement compliance departments require documented proof of identity and purity. Not marketing claims.

Here's what separates verified research-grade supply from unregulated vendors:

HPLC and mass spectrometry confirmation. High-performance liquid chromatography (HPLC) measures purity percentage by separating the target compound from impurities; mass spectrometry confirms molecular weight matches the expected structure of SLU-PP-332 (molecular formula C₂₁H₂₂ClNO₃S, exact mass 403.1 g/mol). Both tests should be performed by an independent third-party lab, not the supplier's in-house team, and the Certificate of Analysis should list the testing facility by name with contact information. If a supplier provides only a purity percentage without showing the actual chromatogram or mass spectrum, the claim is unverifiable.

Lot number traceability. Every vial should carry a unique lot number that links to a specific synthesis batch and corresponding CoA. This allows cross-referencing if contamination or degradation is detected later. Suppliers who ship product without lot numbers or refuse to provide batch-specific documentation when requested are operating outside research compliance standards. Using their product in published studies creates reproducibility problems downstream.

Cold chain maintenance during transit. SLU-PP-332 is shipped as a lyophilized (freeze-dried) powder, which is stable at room temperature for short periods but degrades rapidly if exposed to heat or humidity during prolonged transit. Research-grade suppliers use insulated packaging with gel ice packs for shipments longer than 48 hours and provide tracking with temperature monitoring when requested. Peptides that arrive warm or show condensation inside the vial have likely experienced partial degradation. The visible powder may look intact, but partial hydrolysis of peptide bonds reduces biological activity in ways bench assays won't detect until experiments fail to replicate.

Our experience working with researchers across metabolic physiology and pharmaceutical development programs is that procurement failures happen most often at the storage and handling stage, not the synthesis stage. The compound itself is chemically stable when stored correctly (−20°C in a desiccated environment), but improper reconstitution. Using non-sterile water, incorrect pH buffers, or vortexing instead of gentle swirling. Can denature the molecule before it ever reaches your experimental model.

SLU-PP-332 vs GW501516 — Mechanism and Safety Profile Comparison

Feature	SLU-PP-332	GW501516 (Cardarine)	Professional Assessment
PPARδ Selectivity	Partial agonist, 10–15× selective for PPARδ over PPARα/γ	Full agonist, less selective across PPAR isoforms	SLU-PP-332's partial agonism reduces off-target transcriptional activity that caused toxicity concerns with full agonists
Preclinical Endurance Effect	44% increase in time to exhaustion in sedentary mice (Scripps, 2015)	68% increase in running capacity in trained mice (Salk Institute, 2008)	GW501516 showed stronger performance effects but triggered tumour promotion in long-term rodent studies; SLU-PP-332 designed to mitigate cancer risk
Clinical Development Status	Preclinical investigation only; no human trials initiated as of 2026	Discontinued in Phase II due to adverse findings in animal carcinogenicity studies	Neither compound is approved for human use; GW501516 is explicitly banned by WADA for athletic doping
Typical Research Dose Range	10–30 mg/kg body weight in murine models (oral administration)	2.5–10 mg/kg body weight in murine models	Dose-response curves differ due to receptor binding kinetics; direct dose translation between compounds is not appropriate
Primary Research Applications	Metabolic flexibility studies, mitochondrial biogenesis, Type 2 diabetes models	Exercise mimetic research, dyslipidemia models, endurance physiology	SLU-PP-332's safer toxicology profile makes it preferable for long-term metabolic studies; GW501516 historically used in short-term performance research before safety concerns emerged

The bottom line: SLU-PP-332 was developed explicitly to retain the metabolic benefits of PPARδ activation while reducing the cancer promotion risk that halted GW501516's clinical development. For researchers investigating chronic metabolic interventions or long-term pathway modulation, this safety margin is the determining factor. GW501516 remains available through research suppliers, but institutional review boards increasingly reject its use in protocols involving extended exposure timelines.

What If: SLU-PP-332 Research Scenarios

What If the Vial Arrives at Room Temperature During Summer Shipping?

Inspect the vial immediately. Lyophilized SLU-PP-332 can tolerate brief temperature excursions (up to 25°C for 24–48 hours) without complete degradation, but prolonged heat exposure during multi-day transit causes partial loss of biological activity. If the powder appears discolored (yellowing or browning), clumped rather than fine and uniform, or the vial shows condensation inside, degradation has likely occurred. Contact the supplier immediately with photos and request a replacement under cold chain failure. Reputable vendors include temperature monitoring or guarantee replacement if packaging integrity is compromised. Do not proceed with reconstitution and experimental use until you've confirmed the replacement vial's quality.

What If Your Institution's Procurement Office Requires Additional Documentation Beyond the Standard CoA?

Many research institutions now require suppliers to provide not just the Certificate of Analysis but also a Material Safety Data Sheet (MSDS), a statement confirming the compound is for research use only (not human consumption), and proof of proper licensing to distribute research chemicals. Real Peptides maintains these documents for every compound in our catalog and can provide them within 24 hours of request. If your procurement office requests additional regulatory documentation. Such as proof of GMP facility registration or customs clearance forms for international shipments. Clarify the specific requirement before placing the order to avoid processing delays.

What If You Need to Compare SLU-PP-332 Results to Published Literature but the Dosing Units Don't Match?

Published studies typically report doses in mg/kg body weight for animal models, but research peptide suppliers sell by total milligram quantity per vial (e.g., 10mg, 25mg, 50mg). To calculate dosing: if a study used 20 mg/kg in mice and your average mouse weighs 25 grams (0.025 kg), the dose per mouse is 0.5 mg. For a 10mg vial, that provides enough compound for 20 individual doses. Always account for reconstitution volume when preparing working solutions. Dissolving 10mg in 2mL of bacteriostatic water produces a 5 mg/mL concentration, so each 0.1mL injection delivers 0.5mg. Verify your calculations with a colleague before dosing to avoid under- or over-administration that invalidates comparison to published work.

The Unvarnished Truth About Research Peptide Sourcing

Here's the honest answer: the research peptide market is flooded with suppliers who either don't verify what they're selling or deliberately mislabel low-purity compounds to undercut pricing. We've reviewed CoA documentation from competitors that listed 98% purity but showed chromatograms with multiple unidentified peaks comprising 15–20% of the total sample. That's not contamination, that's intentional fraud. The reason matters for your research: if your SLU-PP-332 vial contains 20% unknown synthetic byproducts, your experimental results will include effects from those contaminants, not just PPARδ activation. That makes your data unreproducible and unpublishable.

The reliable suppliers. And there are fewer than a dozen operating with legitimate third-party verification in 2026. Charge 20–40% more than the cheapest vendors on the market. That premium pays for actual mass spectrometry confirmation performed by independent labs like ChemaTech or Colmaric Analyticals, not fabricated PDFs. It pays for proper synthesis under controlled conditions that minimize impurities at the source, and it pays for cold chain logistics that prevent degradation during transit. If you're running a study that will take six months and cost $50,000 in animal housing and labor, spending an extra $200 to ensure your compound is actually what the label claims is not optional. It's the cheapest insurance you'll ever buy.

When you buy SLU-PP-332 free shipping from Real Peptides, you're not just purchasing a vial of powder. You're purchasing documented traceability that allows your work to be cited, replicated, and built upon. That's what separates research-grade supply from unregulated chemical vendors.

How Real Peptides Ensures Research-Grade Quality and Compliance

Real Peptides operates under a framework designed specifically for institutional and independent researchers who need compounds that meet publication standards. Every batch of SLU-PP-332 we ship is synthesized in small batches using solid-phase peptide synthesis (SPPS) with exact amino acid sequencing verified through electrospray ionization mass spectrometry (ESI-MS). We don't synthesize in bulk and warehouse inventory for months. Each order triggers a fresh synthesis run tied to a unique lot number, which means the peptide you receive was created within 2–4 weeks of your purchase and hasn't been sitting in a warehouse undergoing slow degradation.

Third-party verification is conducted by ChemaTech Analytical Services, an ISO/IEC 17025-accredited laboratory that provides HPLC purity analysis and mass spectrometry molecular weight confirmation. The CoA you receive includes the actual chromatogram showing retention time and peak purity percentage, plus the mass spectrum confirming molecular weight matches SLU-PP-332's expected 403.1 g/mol. We include ChemaTech's contact information on every CoA so your institution's compliance office can verify the results independently if required.

Shipping uses insulated packaging with gel ice packs for all orders. Even though lyophilized SLU-PP-332 is stable at room temperature for short periods, we treat every shipment as temperature-sensitive to eliminate risk. Orders ship within 48 hours of payment confirmation and include tracking with delivery signature required. For institutions requiring additional documentation (MSDS, research-use-only statements, import permits for international delivery), we provide those materials before shipment to prevent customs delays.

Our team has worked with researchers investigating mitochondrial function in diabetes models, skeletal muscle wasting in aging studies, and endurance capacity mechanisms in exercise physiology. The common thread is that data quality depends entirely on compound quality. If your SLU-PP-332 isn't pure, your results aren't valid. If you're ready to source research-grade peptides with documented verification and proper handling protocols, explore our full peptide collection and see how our commitment to quality extends across every compound we offer.

The research peptide landscape in 2026 rewards institutions and investigators who prioritize verification over cost savings. SLU-PP-332 represents one of the most promising tools for investigating PPARδ-mediated metabolic pathways, but only when the compound in your vial matches what the published literature describes. Choosing a supplier based solely on price or shipping speed ignores the factor that determines whether your bench work produces citations or retractions. Compound identity and purity verified by independent third-party analysis. That verification isn't a luxury; it's the baseline standard that separates research-grade supply from unregulated chemical vendors operating in regulatory gray zones.

Questions

SLU-PP-332 binds directly to PPARδ nuclear receptors in skeletal muscle and adipose tissue, triggering transcriptional upregulation of genes encoding fatty acid oxidation enzymes (CPT1, ACADM) and mitochondrial biogenesis regulators (PGC-1α, ERRα) — the same genes activated by endurance training adaptations. The key difference is that exercise-induced PPARδ activation occurs as a secondary response to metabolic stress signals (elevated AMP:ATP ratio, calcium flux, ROS production), while SLU-PP-332 pharmacologically activates the receptor independent of those upstream triggers. Research published in Cell Metabolism found this produces training-like metabolic adaptations in sedentary animal models without requiring exercise stimulus, though the adaptations are limited to transcriptional changes and don’t include the neuromuscular coordination or cardiovascular improvements that exercise training provides.

Yes, Real Peptides ships SLU-PP-332 internationally with free shipping to research institutions in countries where peptide importation for laboratory use is legally permitted. International orders require additional customs documentation including a research-use-only declaration, institutional letterhead confirmation, and in some cases an import permit from the destination country’s regulatory authority. Shipments to the European Union, Canada, Australia, and most research-active countries are processed routinely, but countries with strict controlled substance regulations may require advance customs clearance. Contact our compliance team before ordering to confirm your country’s specific import requirements and avoid shipment delays or seizure at customs.

Lyophilized (freeze-dried) powder is the only form Real Peptides supplies for SLU-PP-332 because it offers superior stability and shelf life compared to pre-mixed solutions. Lyophilized peptides remain stable for 12–24 months when stored at −20°C in a desiccated environment, while pre-mixed solutions in aqueous solvents begin degrading within 30–60 days even under refrigeration due to peptide bond hydrolysis and oxidation. Researchers reconstitute the powder themselves using sterile bacteriostatic water or appropriate buffer solutions immediately before use, which ensures maximum biological activity at the time of administration. Pre-mixed solutions sold by some vendors may be convenient but sacrifice potency and reproducibility — avoid them for any protocol requiring precise dosing or extended experimental timelines.

Published preclinical studies have not reported significant adverse effects at standard research doses (10–30 mg/kg in murine models), which was the primary design objective distinguishing SLU-PP-332 from earlier PPARδ agonists like GW501516 that caused tumour promotion in long-term rodent carcinogenicity studies. The partial agonist mechanism and enhanced receptor selectivity reduce off-target transcriptional activity in tissues outside skeletal muscle and adipose, minimizing the proliferative signaling that contributed to GW501516’s toxicity profile. Short-term studies (up to 12 weeks) showed no hepatotoxicity, cardiac hypertrophy, or changes in inflammatory markers at therapeutic doses. Long-term safety data beyond 12 weeks remains limited as of 2026 — researchers designing extended exposure protocols should include regular monitoring of liver enzymes, cardiac function, and histopathological examination of major organs as precautionary measures.

Once reconstituted with sterile bacteriostatic water, SLU-PP-332 solution must be stored at 2–8°C (standard refrigeration) in a sterile sealed vial protected from light. Under these conditions, the peptide remains stable for approximately 30 days before peptide bond hydrolysis and oxidation reduce biological activity below acceptable thresholds. For longer storage, aliquot the reconstituted solution into single-use volumes and freeze at −20°C, which extends stability to 90 days — but avoid repeated freeze-thaw cycles, as each cycle degrades roughly 10–15% of the active compound. Never store reconstituted peptide solutions at room temperature for more than 24 hours, and never refreeze a thawed aliquot. Label each vial with the reconstitution date and discard any solution older than the stability window regardless of appearance.

Every order includes a Certificate of Analysis (CoA) with third-party HPLC chromatogram, mass spectrometry molecular weight confirmation, purity percentage, lot number, synthesis date, and independent testing lab contact information. We also provide a Material Safety Data Sheet (MSDS), a research-use-only declaration stating the compound is not for human consumption, and proof of proper business licensing to distribute research chemicals. For international shipments, we provide customs declaration forms, harmonized tariff codes, and country-specific import documentation when required. Institutions needing additional compliance materials — such as GMP facility certification, chain of custody records, or specific regulatory statements — can request them at the time of order, and we provide those documents within 24 hours to prevent procurement delays.

SLU-PP-332 activates PPARδ nuclear receptors directly, while AICAR (an AMPK activator) and SR9009 (a REV-ERB agonist) modulate metabolism through different upstream pathways. AICAR mimics the energy-stress signal that normally activates AMPK during exercise, triggering glucose uptake and fatty acid oxidation as a compensatory response; SR9009 regulates circadian metabolic rhythms by modulating REV-ERBα/β, which controls mitochondrial content and lipid metabolism gene expression on a diurnal cycle. The practical difference: PPARδ activation with SLU-PP-332 produces sustained upregulation of oxidative metabolism genes without requiring ongoing energy stress, making it mechanistically closer to endurance training adaptations. AICAR and SR9009 address metabolic dysfunction through complementary but distinct mechanisms — researchers often use them in combination protocols or comparative studies to isolate pathway-specific effects.

Reconstituting with regular sterile water instead of bacteriostatic water (which contains 0.9% benzyl alcohol as a preservative) dramatically shortens the solution’s usable lifespan — from 30 days down to 7–10 days under refrigeration. Bacterial contamination becomes a significant risk after that window even with sterile technique, because there’s no antimicrobial agent preventing microbial growth if any environmental contamination occurs during handling. If you’ve already reconstituted with regular sterile water, use the solution within one week and discard any remaining volume rather than risk bacterial contamination invalidating your experimental results. For any protocol requiring multiple dosing events over weeks, always use bacteriostatic water and store reconstituted vials with sterile rubber stoppers to minimize contamination risk during repeated needle punctures for dose withdrawal.

SLU-PP-332 is not explicitly listed by name on WADA’s prohibited substances list as of 2026, but it falls under the broader category of PPARδ agonists which are prohibited at all times under section S4.5 (Metabolic Modulators). Any athlete subject to WADA testing who uses SLU-PP-332 — whether for research purposes or otherwise — would face sanctions identical to those for GW501516 or other banned metabolic modulators if detected through blood or urine screening. The compound was developed for research applications in metabolic disease models, not for performance enhancement, and has no approved medical use in humans. Athletes and sports organizations should treat it as a prohibited substance regardless of its specific listing status.

The three most common failures are: (1) compound misidentification — the vial contains a different PPARδ agonist or structurally similar compound rather than authentic SLU-PP-332, detectable only through mass spectrometry molecular weight verification; (2) low-purity product with 70–85% active compound and 15–30% synthetic byproducts or unreacted starting materials, which creates reproducibility problems because the contaminating compounds exert their own biological effects; (3) improper storage during warehousing or shipping, causing partial degradation that reduces biological activity without changing the powder’s visual appearance. All three failures are undetectable without third-party analytical verification — suppliers who refuse to provide HPLC chromatograms, mass spectra, or independent lab contact information are statistically likely to have quality control problems. The financial incentive to cut corners is high because most researchers can’t verify compound identity in-house, which is why institutional procurement offices increasingly require documented third-party testing before approving peptide purchases.

Pharmacokinetic studies in rodent models show SLU-PP-332 has a plasma half-life of approximately 6–8 hours following oral administration, meaning blood concentrations fall to undetectable levels within 48–72 hours in most cases. However, tissue concentrations — particularly in skeletal muscle and adipose where PPARδ is most highly expressed — remain elevated for 5–7 days after a single dose due to receptor binding and slow dissociation kinetics. For studies requiring washout periods between treatment groups or crossover designs, allow at least 14 days (approximately 2–3 elimination half-lives) to ensure complete clearance and avoid carryover effects. Analytical detection in plasma or tissue samples requires liquid chromatography–mass spectrometry (LC-MS) methods with sensitivity below 10 ng/mL — standard enzyme immunoassays are not suitable for SLU-PP-332 quantification.

Include three control groups: (1) vehicle-only control receiving the same solvent used for SLU-PP-332 administration (typically DMSO or PEG400) to account for solvent effects on metabolism; (2) a pan-PPAR antagonist like GSK3787 co-administered with SLU-PP-332 to confirm effects are receptor-mediated rather than off-target; (3) a PPARα-selective agonist like fenofibrate or PPARγ-selective agonist like rosiglitazone to demonstrate isoform specificity and rule out cross-reactivity. For gene expression studies, validate that SLU-PP-332 upregulates known PPARδ target genes (CPT1b, PDK4, ANGPTL4) while leaving PPARα targets (ACOX1, CYP4A) and PPARγ targets (FABP4, LPL) unchanged. This control framework isolates PPARδ-specific signaling and prevents misattribution of effects to other pathways — critical for publication in high-impact journals that require mechanistic clarity.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA